COMPASS Pathways Plc (CMPS)' Psilocybin Therapy Hits Phase 3 Success in Depression

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. COMPASS Pathways Plc is one of them.

COMPASS Pathways Plc (NASDAQ:CMPS), a biotechnology company specializing in innovative mental health treatments, is developing COMP360, a psilocybin-based therapy in late-stage development for treatment-resistant depression (TRD). COMP360 has received FDA Breakthrough Therapy designation and has demonstrated promising efficacy in clinical trials.

COMPASS Pathways Plc (NASDAQ:CMPS) recently reported positive primary endpoint results from its first Phase 3 trial, showing a significant reduction in depression symptoms six weeks after a single dose. These results build on prior Phase 2b success, reinforcing COMP360’s potential as a novel psychiatric therapy. The second Phase 3 trial is progressing, with 26-week data expected in the second half of 2026. The business is exploring options for accelerated regulatory filing to bring the therapy to patients more quickly.

Alongside clinical progress, the corporation is advancing commercialization plans to ensure rapid accessibility post-approval. The company maintains a strong cash position of $221.9 million as of June 30, 2025, providing a runway into 2027 for ongoing development and operations. Leadership was bolstered by the appointment of Justin Gover, former CEO of GW Pharmaceuticals, to the Board of Directors, adding governance expertise and strategic oversight.

COMPASS Pathways Plc (NASDAQ:CMPS)  is also investigating COMP360 for other psychiatric conditions, including post-traumatic stress disorder (PTSD) and anorexia nervosa, broadening the potential impact of its psychedelic therapy platform.

While we acknowledge the potential of CMPS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.